Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Will my weight loss plan be customized
What stood out most was the consistent association between GLP-1 receptor agonist use and lower steroid dependence, Dr
According to NICE NG28 guidance: First-line therapy for most people includes metformin (if tolerated) alongside lifestyle modifications SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) may be considered first line for people with established cardiovascular disease, high cardiovascular risk, or chronic kidney disease, offering cardiovascular and renal protection Additional agents may include GLP-1 receptor agonists (e.g., semaglutide, dulaglutide) for weight loss and cardiovascular benefits, DPP-4 inhibitors (e.g., sitagliptin) as a weight-neutral option, sulfonylureas (e.g., gliclazide) to increase insulin secretion, or insulin therapy when other treatments prove insufficient Important medication interactions require attention
)
